January 26, 2009
Sequenom Expands Molecular Diagnostics Portfolio With Acquisition of Sensigen
Sequenom, Inc. announced an agreement to acquire the complete AttoSense™ portfolio of tests along with certain other assets from privately held biotechnology company SensiGen LLC. (Full Story)
September 23, 2008
Sensigen HPV Assay Enables Major Breakthrough in Diagnosis and Treatment of Head and Neck Cancer
Sensigen announces a new program to make the Company's AttoSense™ HPV assay available to head and neck cancer researchers worldwide. (Full Story)
July 30, 2008
Sequenom and Sensigen Expand Global Alliance
Sequenom and Sensigen announce expansion of their global alliance to develop and market advanced diagnostic tests and systems to commercial laboratories worldwide. (Full Story)
April 2, 2008
Sensigen Named "Best Life Sciences Company" by The New Jersey Technology Council
Sensigen was selected for this prestigious award from a pool of more than 50 high profile Life Sciences companies invited to present at the conference. (Full Story)
February 21, 2008
Sensigen receives investment from michigan economic development corporation
Michigan Economic Development Corporation (MEDC) has approved an additional investment in SensiGen to be used for expanding SensiGen’s operations in Ann Arbor. (Full Story)
October 18, 2007
Sensigen Receives Investment From Delaware Crossing
SensiGen LLC announced the closing of an investment from Delaware Crossing Investor Group, a Mid-Atlantic region angel investor group. (Full Story)
Aug 21, 2007
Sensigen Selected as Featured Company at Mac Conference
SensiGen has been selected as one of only 12 life sciences companies to be featured presenters at the upcoming Mid-Atlantic Capital (MAC) Conference. (Full Story)
July 10, 2007
Sensigen Options Epigenetic Biomarkers for Early Detection and Monitoring of Lupus
SensiGen has acquired an option from the University of Michigan to exclusively license a set of epigenetic biomarkers for early detection and monitoring of Lupus. (Full Story)
June 27, 2007
Sequenom and SensiGen Enter into Alliance to Develop and Commercialize Ultra-Sensitive Human Papillomavirus (HPV) Test and Other Advanced Proprietary Diagnostics
Jointly Marketed Tests Could Significantly Improve Early Detection of Major Diseases Including HPV and Cervical Cancer. (Full Story)
May 24, 2007
Sensigen Appoints Jay Stoerker Vice President of Product Development
SensiGen announces the appointment of Dr. Jay Stoerker to the position of Vice President of Product Development. (Full Story)
May 15, 2007
SensiGen Receives Investment from Ann Arbor SPARK
SPARK, the driving force in establishing the Ann Arbor region as a destination for business expansion, retention, and location, has approved a $250,000 investment in SensiGen from the Michigan Pre-Seed Capital Fund. (Full Story)
February 22, 2007
SensiGen Exercises Option to Ultra-Sensitive Human Papillomavirus (HPV) Test
SensiGen has exercised its option to exclusively license an ultra-sensitive Human Papillomavirus – HPV detection test developed at the University of Michigan. (Full Story)
February 12, 2007
World Renowned Scientist Joins Scientific Advisory Board of Sensigen
SensiGen announces that Dr. Nicholas A. Kefalides has joined the company's Scientific Advisory Board. (Full Story)
February 5, 2007
Industry veteran George G. Smith III joins SensiGen
SensiGen appoints George G. Smith III to the post of Senior Vice President for Corporate Development. Mr. Smith will report directly to Shawn M. Marcell, President and Chief Executive Officer of SensiGen. (Full Story)
August 18, 2006
SensiGen Appoints Shawn M. Marcell President and CEO
Science Center senior vice president joins SensiGen team to commercialize leading edge molecular diagnostic technology. (Full Story)
|
